Reuters logo
BRIEF-Ligand to receive $2 mln from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody
August 18, 2017 / 1:07 PM / a month ago

BRIEF-Ligand to receive $2 mln from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody

Aug 18 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand to receive $2 million from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody discovered using the OmniAb technology

* ‍Ligand is also entitled to future milestones and royalties from anti-PD-1 antibody GLS-010​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below